Nanoparticle incorporating Toll-like receptor 4 inhibitor attenuates myocardial ischaemia–reperfusion injury by inhibiting monocyte-mediated inflammation in mice
Authors:
- 9 March 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 115 (7) , 1244-1255
Abstract
Myocardial ischaemia-reperfusion (IR) injury hampers the therapeutic effect of revascularization in patients with acute myocardial infarction (AMI). Innate immunity for damage-associated protein patterns promotes the process of IR injury; however, the blockade of Toll-like receptor 4 (TLR4) in myocardial IR injury has not been translated into clinical practice. Therefore, we aimed to examine whether the nanoparticle-mediated administration of TAK-242, a chemical inhibitor of TLR4, attenuates myocardial IR injury in a clinically feasible protocol in a mouse model. We have prepared poly-(lactic-co-glycolic acid) nanoparticles containing TAK-242 (TAK-242-NP). TAK-242-NP significantly enhanced the drug delivery to monocytes/macrophages in the spleen, blood, and the heart in mice. Intravenous administration of TAK-242-NP (containing 1.0 or 3.0 mg/kg TAK-242) at the time of reperfusion decreased the infarct size, but the TAK-242 solution did not even when administered at a dosage of 10.0 mg/kg. TAK-242-NP inhibited the recruitment of Ly-6Chigh monocytes to the heart, which was accompanied by decreased circulating HMGB1, and NF-κB activation and cytokine expressions in the heart. TAK-242-NP did not decrease the infarct size further in TLR4-deficient mice, confirming the TLR4-specific mechanism in the effects of TAK-242-NP. Furthermore, TAK-242-NP did not decrease the infarct size further in CCR2-deficient mice, suggesting that monocyte/macrophage-mediated inflammation is the primary therapeutic target of TAK-242-NP. The nanoparticle-mediated delivery of TAK-242-NP represent a novel and clinical feasible strategy in patients undergone coronary revascularization for AMI by regulating TLR4-dependent monocytes/macrophages-mediated inflammation.Keywords
Funding Information
- Ministry of Education, Science, and Culture, Tokyo
- Grants-in-Aid for Scientific Research (17K16011, 17K09590)
- JST CREST (JPMJCR17H5)
- Intractable Diseases Overcome Research Project
- Japan Agency for Medical Research and Development
This publication has 50 references indexed in Scilit:
- Role of Extracellular RNA and TLR3‐Trif Signaling in Myocardial Ischemia–Reperfusion InjuryJournal of the American Heart Association, 2014
- Door-to-Balloon Time and Mortality among Patients Undergoing Primary PCINew England Journal of Medicine, 2013
- Pharmacological inhibition of TLR4-NOX4 signal protects against neuronal death in transient focal ischemiaScientific Reports, 2012
- Nanoparticle-Mediated Delivery of Pitavastatin Into Lungs Ameliorates the Development and Induces Regression of Monocrotaline-Induced Pulmonary Artery HypertensionHypertension, 2011
- A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*Critical Care Medicine, 2010
- Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarctionClinical Science, 2008
- Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion InjuryPhysiological Reviews, 2008
- The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functionsJournal of Experimental Medicine, 2007
- Reduced Myocardial Ischemia-Reperfusion Injury in Toll-Like Receptor 4-Deficient MiceCirculation, 2004
- Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injuryCardiovascular Research, 2004